Dr Reddy's launches anti-nausea injection for cancer patients in US

Drug is a therapeutic equivalent of USFDA-approved Aloxi injection, whose sales in 12 months to Jan 2018 were $446 mn

Pharmaceuticals, drugs, pharma industry, medical, health, lab
BS Reporter Hyderabad
Last Updated : Mar 26 2018 | 12:05 PM IST
Dr Reddy's Laboratories Limited announced on Monday that it has launched Palonosetron Hydrochloride Injection, 0.25 mg/ml, a therapeutic equivalent of Aloxi Injection approved by the US Food and Drug Administration (USFDA).

The drug is used to treat chemotherapy-induced nausea and vomiting sensation. 

The Aloxi brand and generic had US sales of approximately $446 million for twelve months ending in January 2018, according to IMS Health.

Dr Reddy's injection is available in a single-dose vial packed in a carton containing one vial, according to the company. 

The shares of the company were trading at Rs 2,060, down 0.67 per cent, at around 11:30 a.m. on the Bombay Stock Exchange on Monday. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story